



SymBio Pharmaceuticals Limited

San-Ei Building, 5-23-7 Shimbashi, Minato-ku, Tokyo 105-0004, Japan
Tel: +81-3-5472-1125 Fax: +81-3-5472-3054 <http://www.symbiosis.co.jp/>

February 27, 2009

SymBio Pharmaceuticals Limited

Fuminori Yoshida

Representative Director
President and Chief Executive Officer

TREANDA® (Cephalon, Inc.) is selected as a finalist as Pharmaceutical Executive Magazine's 'Brand of the Year'

TREANDA®, which is marketed by Cephalon, Inc. in the US after receiving US FDA approval for CLL and Relapsed Indolent NHL in March and October of 2008, respectively, was selected as one of three finalists for Pharmaceutical Executive Magazine's 'Brand of the Year' in 2008. TREANDA® was selected as it became the first advance against CLL in seven years

In December 2008, ASCO (The American Society of Clinical Oncology) announced its annual list of 12 major advances in cancer treatment and prevention. The selections were made by the 21 cancer specialists who make up ASCO's editorial board. TREANDA® for CLL was chosen due to a different mode of action that may work against a wide range of blood cancers.

SymBio Pharmaceuticals Ltd. holds exclusive rights from Astellas Deutschland GmbH to develop and market bendamustine HCl in Japan, China (HK), Taiwan, Korea and Singapore.

SymBio and Eisai Co., Ltd. executed a license agreement for the co-development and commercialization of SyB L-0501 in Japan in August 2008. The Phase II clinical trial for the treatment of patients with relapsed indolent NHL, and Phase I trial for the treatment of patients with relapsed aggressive NHL in combination with Rituximab, are now being conducted in Japan.

[Company Profile]

SymBio Pharmaceuticals Ltd. was established in March 2005 by Fuminori Yoshida, who previously served as both Corporate VP of Amgen Ltd. and President of Amgen Japan (currently Takeda Bio Development Center Limited). The company's underlying corporate philosophy is "delivering hope to patients in need," and the company aims to address unmet medical needs of patients in Japan and other Asia Pacific regions by cultivating a mutually beneficial or symbiotic relationship among physicians, scientists, investors, government, and patients in the healthcare industry.

[Contact]

SymBio Pharmaceuticals Limited.

IR inquiry desk, Corporate Division

Tel: +081(0)3 5472 1125

e-mail: Please send your inquiry through "INQUIRY" in our homepage

URL: <http://www.symbiosis.co.jp>